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Background: collagen VI-related myopathy is one of the 
most common type of congenital muscular dystrophy. This 
study was aimed to describe clinical, genetic 
characteristics, and identify their association of collagen 
VI-related myopathy patients.
Methods: We enrolled 23 patients with collagen VI-related 
myopathy who were confirmed to have pathogenic mutation 
of COL6A1, COL6A2, COL6A3. Medical record was 
reviewed retrospectively.
Results: Among 23 cases, 10 patients (43%) had congenital 
orthopedic problems such as torticollis, congenital hip 
dislocation or arthrogryposis congenita. Three patients 
(13%) never walked and 7 (35%) lost their walking ability 
later at the mean age of 10. Hyperlaxity of distal joints, 
contracture of proximal joints, and scoliosis were noted 
each in 12 (52%) patients. Six patients (26%) used 
mechanical ventilator support. Clinical features and courses 
varied by patients. Patients were categorized as Ullrich 
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type in 11 (48%), Bethlem type in 4 (17%), limb-girdle type 
in 3 (13%), and undetermined in 5 (22%). All patients 
showed sarcolemma-specific collagen VI deficiency in 
immunohistochemistry of muscle. Mutations for COL6A1, 
COL6A2, and COL6A3 were found each in 15 (65%), 3 
(13%), and 5 (22%) of each group of patients. All had 
heterozygous variants and most of mutations located in 
triple helical domain. Five novel variants were detected. 
There was no clear association between genotype and 
phenotype. Multiple congenital orthopedic problems 
including arthrogryposis multiplex congenital were 
frequently noted in early-severe group.
Conclusion: We verified heterogeneity in clinical features of 
collagen VI myopathy as well as in pathology and genotype. 
Multiple congenital orthopedic problems might suggest poor 
prognosis, without clear genotpye or phenotype association 
to clinical severity.
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Congenital muscular dystrophies (CMDs) are genetically and 
phenotypically heterogeneous group of disorders characterized 
by early onset weakness or motor development delay with 
dystrophic change on muscle biopsy. Its heterogeneity have 
made detailed diagnosis very challenging, yet the diagnosis is 
crucial for patients’ management, predicting the prognosis and 
counseling the patient and family due to properties such as 
lifelong disease course without curable treatment. Traditionally, 
CMDs had been classified according to pathologic and clinical 
features. However, development in the knowledge of genetic 
backgrounds has allowed a novel classification of CMDs 
according to genetic defect [1]. Among them, collagen VI-
related myopathy (COL6 myopathy) is a genetically classified 
subtype of CMDs caused by mutation of COL6 genes, COL6A1, 
COL6A2, COL6A3. Each genes encode for three α-chains of 
collagen VI, and each chains are assembled into collagen VI 
protein. Collagen VI is an extracellular matrix protein found in 
most of tissues, and its absence or aberrant formation in muscle 
cause myopathies. Most well-known phenotype of COL6 
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myopathy is Ullrich congenital muscular dystrophy (UCMD, MIM 
254090), characterized by early onset muscle weakness, 
hyperlaxity of the distal joint, contracture of proximal joint, 
scoliosis and respiratory insufficiency [2]. Bethlem myopathy 
(BM, MIM 158810) is the other form of COL6 myopathies [3-5], 
considered as milder phenotype, mainly characterized by joint 
contractures (commonly finger flexors, wrist, elbow and ankle) 
with slowly progressive muscle weakness mainly starting in the 
first 2 decades of life [4, 6]. It is well known that there are no 
clear clinical criteria to distinguish two phenotypes, and each 
phenotype is on each end of clinical continuum. Moreover, limb-
girdle muscular dystrophy (LGMD) or myosclerosis myopathy 
were reported as other phenotypes of COL6 myopathy [7, 8]. 
The clinical boundaries between phenotypes have become more 
blurred according to expanding and overlapping spectrum, on the 
strength of recently growing genetic testing and increased 
number of reports. In genetic backgrounds, the mutation on same 
domain caused different phenotype, and both autosomal dominant 
and recessive patterns were observed in either UCMD or BM 
[9-12]. There have been many studies for each UCMD or BM, 
though clinical reports on overall clinical and genetic aspects of 
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COL6 myopathies were still limited [13]. We have therefore 
attempted to descript the various clinical spectrum of COL6 




1. Patients and phenotype classification
From August 2000 to July 2016, we screened patients with 
CMD unclassified by conventional diagnostic tools in Seoul 
National University Children’s Hospital. Total 156 patients had 
targeted gene panel sequencing with or without Sanger 
confirmation of their parents. Among them, 23 patients who were 
confirmed to have pathogenic mutation in COL6A1, COL6A2 or 
COL6A3 were enrolled. The medical records including past 
medical history, physical examination findings, laboratory test, 
radiographic findings, and functional studies such as 
echocardiography or pulmonary function test and muscle 
pathology were reviewed. Informed consent for genetic testing 
was obtained in all patients and the study was approved by the 
Institutional Review Board (IRB) of the Seoul National University 
Hospital. (IRB No. 1610-080-799)
We classified the patients into 4 phenotypes, UCMD, BM, LGMD 
and undetermined, for identifying clinical spectrum of disease. 
The Patients with UCMD were defined as congenital or infantile 
onset progressive muscle weakness, hyperlaxity of distal joint, 
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contracture of proximal joint with relatively early-onset of 
scoliosis and loss of their walking ability. Subgrouping of BM 
was based on the clinical features including muscle weakness 
predominantly in the proximal and axial muscle, early joint 
contractures especially in finger flexor, wrist, or ankle and 
relative preserved motor performance without ventilator support. 
We categorized LGMD phenotype apart from BM, in the patients 
with proximal, axial, especially neck muscle weakness without 
joint contractures or rigid spine. The patients who did not belong 
in any three groups were classified into undetermined group. 
Congenital hip dislocation was defined as unilateral or bilateral 
dislocation of hip joint, which was thought to be occurred their 
birth, arthrogryposis multiplex congenita and congenital 
torticollis were diagnosed by pediatric orthopedic doctors after 
patient’s birth. All neurological assessment was performed by a 
qualified pediatric neurologist. Immunohistochemistry for collage 
VI was performed in 20 patients and reviewed by the same 
pediatric neurologist.
2. Targeted genes analysis
Sequencing analysis was performed in separate 2 centers, 
Seattle Children ’ s Hospital and Seoul National University 
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Children’s Hospital. Eleven patients (patient No.1, 7, 8, 9, 10, 11, 
12, 13, 15, 16, and 18) have sequencing for target genes at 
Seattle Children’s Hospital and remained patients (patient No. 2, 
3, 4, 5, 6, 14, 17, 19, 20, 21, 22, and 23) in Seoul National 
University Hospital. Sequencing data from Seattle Children ’ s 
Hospital was included in the previous study [13]. The target 
genes for various neuromuscular diseases were included in both 
centers; CMDs, congenital myopathies, metabolic and 
mitochondrial myopathies, storage myopathies, distal myopathies, 
channelopathies, disease of neuromuscular junction and 
peripheral nerve. In Seattle Children’s Hospital 579 genes were 
included, which were revealed in Appendix 1 [13], and Gene 
lists for sequencing in Seoul National University were indicated 
in Appendix 2 (total 434 genes) [14]. Genomic DNA was 
extracted from peripheral blood leukocytes using a QIAamp®
DNA Blood Midi Kit according to the manufacturer’s instructions 
(Qiagen, Valencia, CA, USA). A DNA library was prepared for 
each sample by capturing the exons of the genes of interest 
using custom made DNA probes (Haloplex Agilent, Santa Clara, 
California, USA) in both centers. Samples were sequenced at 5–8 
samples per lane on a GAIIx instrument (Illumina, San Diego, 
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California, USA) using 2×100 paired-ends reads in Seattle 
Children’s Hospital and on the Hiseq 2000 sequencing system
(Illumina HiSeq 2500, San Diego, California, USA) using 2 × 101
paired-end reads. Reads were aligned using Burrows-Wheeler 
Aligner (BWA, V.0.7.3) and data were analyzed with the Genome 
Analysis Toolkit (GATK, V.2.4.9) (Broad Institute, Cambridge, 
Massachusetts, USA) [15].
3. Variant annotation and identification of mutations
Variants were annotated using SeattleSeq [16] and wAnnovar 
[17]. Variants within the targeted region were further evaluated 
by cross-referencing to Single Nucleotide Polymorphism 
Database (dbSNP), the exome variant server, and the 1000 
Genomes browser. PolyPhen-2 and SIFT (sorting intolerant from 
tolerant) scores were used for reference. We used the minor 
allele frequency (MAF) cut-off 0.2% for variants in genes with 
autosomal dominant or X-linked inheritance, and 0.5% for 
autosomal recessive variants [15]. If the variant exceed these 
frequencies, we considered the variant as non-pathogenic. Also, 
all variants were searched in the Human Gene Mutation Database 
(HGMD) [18, 19]. The sequence variants were interpreted based 
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on the guideline from American College of Medical Genetics [20]
4. Direct Sanger sequencing
For confirmation of variants, direct sequencing of the coding 
exon which included pathogenic variants of COL6A1, COL6A2, or 
COL6A3 was performed using primer pairs designed by the 
authors, which are available upon request. Polymerase chain 
reaction amplification was performed in a thermal cycler (Model 
9700; Applied Biosystems, Foster City, CA, USA) and cycle 
sequencing was performed on an ABI Prism 3730xl DNA 
Analyzer using the BigDye Terminator Sequencing Ready 
Reaction Kit (Applied Biosystems). Sequencing for trio (the 
patient and parents) was available in 17 patients (patient No. 1-
13, 15-18). Validation for the patient No. 14 was performed only




Among 23 patients enrolled in the study, 14 (60%) were male 
and 9 (40%) were female. The mean age at last assessment was 
12 years old (range, 2-29 years old) and mean follow-up 
duration was 7.7 years (range, 0-21 years). Clinical 
manifestations and phenotype of all patients are shown in Table 
1. Fifteen patients (65%) had some perinatal abnormalities. 
Congenital hip dislocation, torticollis and arthrogryposis 
multiplex congenita were noted in 7 (30%), 5 (21%) and 3 (13%) 
patients, respectively. Perinatal distress such as poor sucking, 
respiratory difficulty or decreased muscle tone were reported in 
9 (39%) of patients. The mean age at first symptom recognition 
was 24 months of age (range, 0-156 months). The most of 
patients (19 patients, 82%) initially presented with hypotonia 
since their birth (6 patients, 26%) or motor developmental delay 
before 24-month-old (13 patients, 56%). One patient (patient No. 
1) was believed to have muscular disorder due to severe 
hyperlaxity of both hands and feet since her birth. The patient 
No. 8 initially presented with tip toeing since 6 years of age and 
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the patient No. 12 have showed progressive weakness in lower 
extremities since 7 years old. The patient No. 14 was brought to 
hospital due to limping gait starting since his age of 13. Six 
patients (26%) could walk alone before 15 months of age, 
whereas 3 (13%) never walked. Among 20 patients who had 
walked alone once, seven (35%) lost their walking ability at 
mean age of 9 years old (range, 4-11 years). Last motor 
performance was varies according to each patients, from running 
to near bed ridden state. Hyperlaxity of distal joints and 
contracture of proximal joints were noted each in 11 (48%) of 
patients. Twelve patients (52%) had various degree of scoliosis 
and 3 were treated surgically. Six patients (26%) used non-
invasive positive pressure ventilator during sleep, with the mean 
starting age of 11 years (range, 9-13). Patients were 
categorized by clinical phenotype, as UCMD in 11 (48%), BM in 4 
(17%), LGMD in 3 (13%) and undetermined in 5 (21%). None of 
the patients had cardiac problems, and intelligence was grossly 
normal in all patients except the patient 15, who could say a 
word only at 4 years of age and delayed cognitive function with 
perinatal history of neonatal respiratory difficulty and stay in 
neonatal intensive care unit. Muscle biopsy was done in all the 
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patients, with various performed age (range from 6 months to 29 
years old). The pathology findings indicated various degree of 
dystrophic change and endomyseal fibrosis. The degree of size 
disproportion or muscle fiber integrity seemed to be not 
associated with the age of tissue securement. 
Immunohistochemistry of collagen VI was obtained in 20 patients, 
all revealed sarcolemma-specific collagen VI deficiency (SSCD).
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Table1. Clinical features of the patients
No Age/Sex
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feet





Hypotonia 0 18 4
Near bed 
ridden
+ + +, surgery + UCMD SSCD

































+ - - - UCMD SSCD










Tip toeing 60 18 Not yet
Walk with 
waddling
- + + - LGMD SSCD
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Motor delay 12 12 Not yet Walk alone + - + - BM SSCD
11 9/M Hypotonia Motor delay 12 15 Not yet
Run, step 
up




















+ - + - Undetermined SSCD














Motor delay 24 NEVER NA
Walk with 
assist in the 
pool







Motor delay 18 NEVER NA
Walk alone
Cannot run 
or step up 
+ + - - UCMD SSCD




- - - - LGMD SSCD




- + - - BM SSCD
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19 12/M - Motor delay 8 13 11
Walk alone, 
step up with 
holding the 
bar
+ - - - UCMD NA









Hypotonia 0 19 Not yet




+ + - - UCMD NA













- - + - Undetermined SSCD
NIV = non-invasive ventilator, IHC = immunohistochemistry, UCMD= Ullrich congenital muscular dystrophy, SSCD = 
sarcolemma-specific collagen deficiency, BM = Bethlem myopathy, LGMD = limb girdle muscular dystrophy, NA = not available,
WB = wheelchair bounded
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2. Mutation profiles
Target gene panel sequencing was performed in all patients and 
16 different variants (10 in COL6A1, 2 in COL6A2, 4 in COL6A3) 
were found. All except one variants were missense (11 patients, 
48%) or splicing site mutation (11 patients, 48%). Genetic and 
immunohistochemistry findings of all patients are shown in Table 
2. Fifteen patient (65%) had a COL6A1 variant, each 2 (13%) and 
5 patients (22%) had COL6A2 and COL6A3 variant. The 
mutations of c.850G>A of COL6A1 was the most frequent single 
variant. All patients indicated dominant heterozygous variants. 
The patient No. 14 initially showed compound heterozygous 
mutations of c.350C>A and c.349T>A which were both novel 
variants, yet c.349T>A was seemed to be not damaging 
according to our variant identification protocol. The most of 
mutations (14 of 16 variants, 88%) were located in triple helical 
domain. Seventeen patients underwent direct Sanger sequencing 
with parents analysis. Among them, 13 patients had De novo
mutations, whereas 4 patients inherited from one of their parents. 
Among 4 parents with the same variant, 2 showed similar 
symptoms with their children, while other 2 had no clinical 
symptoms (the patient No. 1 and 15). Five of total 16 variants 
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have never been reported so far with our knowledge, and other 5 
variants of 11 previously reported mutations were first identified 
in our cases but they have already reported in the previous 
article of our group [13]. Muscle biopsy was done in all the 
patients, with various performed age (range from 6 months to 29 
years old). The pathology findings indicated various degree of 
dystrophic change with endomyseal fibrosis. 
Immunohistochemistry of collagen VI was obtained in 20 patients, 
all revealed sarcolemma-specific collagen VI deficiency (SSCD). 
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Table 2. Mutation profiles of the patients
Patient 
No
Gene Nucleotide change Amino acid change Affected domain Inheritence Reference




2 COL6A1 c.958-2A>G Splicing site THD De novo Novel




















THD De novo CM050215
9 COL6A1 c.1002+1delG Frameshift THD De novo CD151671*


























THD De novo Novel





20 COL6A1 c.859-2A>G Splicing site THD NA Novel





23 COL6A2 c.801+1G>A Splicing site THD NA Novel
* first reported in previous study of our cohort, the same patient [13]
†father sample unavailable
COL6 = collagen VI, THD = triple helical domain, NA = not available
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3. Phenotypic analysis with genetic data
Core clinical and genetic data for each phenotype is summarized 
in Table 3. UMCD patient showed first symptom at younger age 
(mean age 6 months) with more perinatal distress and congenital 
orthopedic problems than non-UCMD patients (mean age 40 
months). Congenital orthopedic problems in 4 non-UCMD 
patients were torticollis or congenital dislocation of hip, and only 
one patient had both of them. The arthrogryposis congenita was 
noted only in UCMD patients. All 3 patients with arthrogryposis 
congenita also had another orthopedic problems (torticollis or 
congenital hip dislocation) and 2 of them never walked and the 
other patient could walk independently at last assessed age of 
2.7 years. Eight UCMD patients (73%) never walked or loss of 
their walking ability at mean age of 9.4 years (range, 4.3-11.8) 
in comparison with 10 patients (83%) still could walk at last 
assessed age of 14 years in non-UCMD group. Mutation in 
COL6A1 accounted for 8 (73%) in UCMD and 8 (66%) in non-
UCMD patients. All two variants in COL6A2 were found in 
undetermined patients only. Each 3 (27%) in UCMD and 2 (17%) 
in non-UCMD patients had variants in COL6A3. Most of affected 
domain (91%) was triple helical domain. One patient with UCMD 
20
indicated variant in C4 domain, and one with non-UCMD had 
mutation in N1 domain. We also identified the mutation type 
according to phenotypes. Single amino acid substitution in exon 
accounted for 36% and 58% of UCMD and non-UCMD patients. 
Mutation in splicing site was documented in 7 (64%) of UCMD 
patients and 4 (33%) of non-UCMD patients. Three patients who 
never walked had an amino acid substitution in COL6A1 (patient 
No. 6), and two splicing site mutation in COL6A3 (patient No. 15 
and 16). One frameshift mutation in COL6A1 was found in patient 
with BM. Other 3 patients with BM showed splicing site mutation. 
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Table 3. The summary of clinical and genetic data in each phenotype

































8:3 6 7 (64) 7 (64)
NW, 3 (27, 7 years)
LOA, 5 (46, 13 years)
SW, 3 (27, 5 years)








6:6 40 4 (33) 2 (17) LOA, 2 (17, 10 years)
SW, 10 (83, 14 years)






     BM
                      
(n=4)
2:2 16 1 (25) 1 (25)
LOA, 1 (25, 7 years)
SW, 3 (75, 12 years)
3 (75) 0 (0) 1 (25) THD, 4 (100)
Splicing 3 (75)
FS, 1 (25)
     
LGMD
     
(n=3)
2:2 74 1 (25) 0 (0) SW 3 (100, 7 years) 22 (67) 0 (0) 1 (33) THD, 3 (100) AAS, 3 (100)
     UD
     
(n=5)
2:2 30 2 (50) 1 (25)
LOA 1 (20, 13 years)
SW, 4 (80, 22 years)





UCMD = Ullrich congenital muscular dystrophy, BM = Bethlem myopathy, LGMD = limb girdle muscular 
dystrophy, UD = undetermined, NW = never walked, LOA = loss of ambulation, SW = still walking, THD = 
triple helical domain, AAS = amino acid substitution, FS = frameshift
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DISCUSSION
Despite the true incidence of total CMDs and COL6 myopathy 
has not been established and might vary across the countries, 
there is no doubt that COL6 myopathy is one of the most 
common type CMDs. It has been considered as second most 
common type in Japan [21], accounting for 9.4% of all CMDs, 
and UCMD with mutation in collagen VI genes accounts for 16% 
of all CMD cohort in Italy [22]. According to the previous study, 
COL6 myopathy is the most common type in our cohort [13]. 
Considering its frequency, profound understanding and 
investigation for COL6 myopathy is crucial for patients’ care as 
well as CMD research.  
The concept of COL6 myopathy has evolved over years. Each 
UCMD and BM had described separately at first [2, 4], yet both 
have been considered to be in a line of clinical spectrum since 
the causative genes found [9, 11]. In genetic backgrounds, it is 
well known that UCMD and BM might be caused by dominant and 
recessive trait either, unlike their first report of recessive 
inheritance pattern in UCMD and dominant inheritance in BM [8-
11]. Phenotypes of COL6 myopathies also have been expanded 
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over years, referred to intermediate collagen VI-related 
myopathy, mild UCMD or severe BM [23]. Moreover, 
phenotypes such as LGMD-like or myosclerosis myopathy with 
mutation in collagen VI gene were reported so that simple 
clinical approach could miss the diagnosis. In our cohort, five 
patients were categorized as undetermined. Among them, the 
patient No. 13 presented limping gait since age of 13 years 
without any perinatal problems, and he is still able to walk or 
step up at present (27-year-old), but showed distal lower leg 
weakness and foot drops without proximal weakness, mimicking 
distal myopathy. The patient No. 23 was brought the hospital due 
to moderate to severe motor developmental delay at age of 18 
months. She could walk alone past over 4 years of age, but still 
walk independently without respiratory compromise. On the 
other hands, the patient No.12 presented with progressive 
weakness of lower extremities since her age of 7 years. Despite 
of progressive weakness, she can still walk independently and 
step up with holding the bar, at age of 20 years. However her 
respiratory function have rapidly declined as functional vital 
capacity below 25%, so she have used night time non-invasive 
positive pressure ventilator since her age of 13 years. Likewise, 
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COL6 myopathy showed diverse phenotypes and severities 
without typical characteristics of collagenopathy including joint 
problems and clinical course of skeletal muscle weakness 
following respiratory compromise, as well as classical UCMD, 
BM, or intermediate phenotype. We expand the clinical spectrum 
with those cases of COL6 myopathies, helpful in clinic to 
diagnosis and management, as well as broadening academic 
perspectives. 
According to expansion of genetic study especially gene panel 
or whole exome sequencing, heterozygous mutations have been 
frequently found [24], and recent study indicated that dominant 
mutation is the major genetic backgrounds even in UCMD [25, 
26]. In our study, all patients revealed heterozygous mutation, 
supporting evidence of majority of dominant variant in UCMD. It 
has been well known that glycine substitutions in the triple 
helical domains (THD) are most common site for mutations of 
COL6 myopathy [12, 27], consistent with the present study. The 
variants distribution for each gene varied by studies each, yet 
variants in COL6A2 accounted for 13% in our study, less 
frequent compared with 35-48% in other studies [12, 21, 28]. 
The patient No. 1 and 15 had heterozygous variant 
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(c.1461+3G>C in COL6A1 and c.9329-4A>T in COL6A3) 
inherited from their parents without any clinical symptoms. We 
conclude that these variants pathogenic based on previous report, 
patients’ immunohistochemistry (IHC) findings and our variant 
analyzing protocol. Therefore the condition was thought to 
“ incomplete penetrance ” . Incomplete penetrance in 
collagenopathy was only reported in COL6A1 splicing site 
mutation leading to premature stop codon [29]. In three UCMD 
family with homozygous mutation of COL6A3, all parents who 
were heterozygous carrier showed no clinical symptom yet the 
one young offspring with heterozygous variants have started to 
indicated joint symptoms [30]. Our 2 splicing site mutation in 
COL6A1 and COL6A3 might be another evidence of variable 
penetrance. Further study for unknown modifier of COL6 
myopathy is needed.
In pathology, similar to the inheritance type, SSCD have been 
rapidly increased since its first description [31]. It is well known 
that complete deficiency (CD) and SSCD are associated with 
recessive and dominant mutation each, although it doesn’t always 
coincide. Our patients, all with heterozygous mutations, indicated 
SSCD in this context. The degree of SSCD was also diverse (Fig. 
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1), and some IHC findings were very tricky to diagnosis without 
genetic analysis, might be due to interstitial fibrosis in some 
patients. In these cases, pathology gave only limited information 
and genetic study could performed a key role for diagnosis. In 
fact, genetic technology such as gene panel sequencing or 
whole-exome sequencing have been ranked gold standard to 
diagnosis of CMDs. Nevertheless, pathologic findings can 
provide some clues for diagnosis with clinical information 
together, because target gene panel sequencing cannot confirm 
the final diagnosis by itself. Therefore, overall comprehension in 
patients ’ phenotype, biopsy findings including IHC, and 
appropriate genetic test and interpretation is needed to exact 
diagnosis.
Over 300 pathogenic variants in COL6A1, COL6A2, and 
COL6A3 have been reported [32]. The correlation between 
genotype and phenotype have been difficult to analyze and 
seemed to be not so clear, due to their heterogeneity and 
genetic overlapping across the phenotypes. So far, glycine 
substitution in a critical region near the N-terminal THD has 
thought to be associated with severe phenotype in some patients 
might be due to reduced collagen VI as well as assembly 
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abnormality. But in the same study, another patients with same 
mutation showed phenotype with normal amounts of collagen 
[33]. Two patients with homozygous premature stop codon (PTC) 
mutations were reported as severe phenotypes, yet the other 
patient with homozygous PTC showed mild phenotypes [12]. 
Recent study in Japan revealed that there were no clear 
genotype-phenotype correlations [21]. No definite genotype-
phenotype association was observed in our study, either. In our 
cohort, 9 patients (39%) revealed glycine substitution in THD 
domain. No patient had homozygous mutations and only one 
patient had heterozygous frameshift mutation. Most of them was 
located in THD and showed various phenotypes and clinical 
severities. Three patients who never walked in the present study 
had one missense glycine substitution and two splicing mutations 
each. Among them, the patient with common missense glycine 
substation (c.850G>A in COL6A1), who is 4-year-old girl, could 
elevate her arm up to shoulder only. The heterozygous missense 
mutation of c.850G>A in COL6A1 is one of the most common 
variant in various phenotype [34]. We found the variant in 5 
patients (22%, patient No. 4, 5, 6, 12, and 13), who showed 
extremely variable clinical features from never walking (patient 
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6) to walking freely at age of 20 (patient No. 12). Pathology 
findings are also extremely heterogeneous, in both Hematoxylin-
Eosin (HE) stain and collagen VI IHC. The Fig. 2 indicated HE 
and IHC of collagen VI findings in 3 patients with c.850G>A 
heterozygous variants, which revealed various degree of 
dystrophic change and deficiency of collagen VI. The pathology 
of the patient 6 indicated severe dystrophic change with 
moderate to severe endomyseal fibrosis, whereas that of the 
patient 13 revealed relatively mild dystrophic change only and 
less obvious deficiency in collagen VI expression. The 
phenotypic heterogeneity in the same mutation is s also 
indicative of the presence of other modulator for COL6 myopathy. 
To predict the disease severity and prognosis, phenotypic 
classification have been considered the priority. As previously 
shown in Table 3, UCMD patients seemed to have sever 
phenotype compared with non-UCMD patients. Nevertheless, it 
didn’t always coincide. The patient No. 1 presented with UCMD 
could still walk and hop in one leg at her age of 9 years, whereas 
the patient No. 18 initially presented with mild phenotype 
followed by rapid deterioration of muscle power and wheelchair 
bounded at 6 years old. Also, patients showed variable clinical 
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courses in age of first walking, max motor performance and 
velocity of deterioration even in the same phenotype. Therefore, 
early phenotypic classification could not show patients ’
prognosis exactly and long term follow-up and serial assessment 
for patients might be only way to predict outcome and provide 
appropriate management. Exceptionally, all patients with 
arthrogryposis congenita had also combined other orthopedic 
problems and devastating clinical courses. We carefully suggest 
that multiple orthopedic problems especially multiple joints 
contracture might be helpful to predict poor outcome in early 
period of disease. 
In conclusion, our data might expand the clinical spectrum with 
some novel variants, as well as reinforcement of previous study 
relating to heterogeneity and complexity of COL6 myopathy. 
Clinical diversity and incomplete penetrance indicated the 
presence of additive modifier in COL6 myopathy. There were no 
clear genotype-phenotype correlation and phenotypic 
classification was hard to predict patients ’ outcome. 
Exceptionally, multiple congenital orthopedic problems could be 
the predictor for poor outcome. 
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Figure 1. Heterogeneity of collagen VI immunohistochemistry (IHC) 
findings. 
Each indicated (A) relatively preserved integrity of muscle fibers and 
not clear collagen VI deficiency (patient No. 4, muscle biopsy done at 
10 years old) (B) relatively preserved integrity and more obvious 
collagen VI deficiency (patient No. 15, muscle biopsy done at 4 years 
old) (C) severe fiber size variation with fibrosis and sarcolemma-
specific collagen VI deficiency (patient No. 17, muscle biopsy done at 




biopsy done at 2 years old). 
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Figure 2. Pathology findings of the patients with c.850G>A in COL6A1. 
Hematoxylin-Eosin stain and immunohistochemistry of collage VI findings in the patient 5 (A, D, muscle 




F, muscle biopsy done at 5 years old), which showed different degree of dystrophic change and collagen VI 
deficiency each other.
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Appendix 1. List of Genes for targeted gene panel sequencing in Seattle Children’s Hospital (total 579 genes)
Congenital Myoapthy (30)
ACTA1, ACTG2, ATP2A1, BIN1, CCDC78, CFL2, CLCN1, CNTN1, DNM2, FAM123B, FLNC, GNE, OXD10, HRAS, 
KBTBD13, LDB3, MEGF10, MTM1, MTMR14, MYF6, MYH2, MYH7, NEB, TIA1, TNNT1, TPM2, TPM3, TTN, VCP, 
VMA21
Muscular dystrophy (48)
ANO5, BAG3, CAPN3, CAV3, CHKB, CNBP, COL6A1, COL6A2, COL6A3, CRYAB, DAG1, DES, DMD, DMPK, DNAJB6, 
DPM2, DPM3, DYSF, EMD, FHL1, FKBP14, FKRP, FKTN, GTDC2, ISPD, ITGA7, ITGA9, KLHL9, LAMA2, LARGE, 
LMNA, MTAP, MYOT, PABPN1, PLEC, PLOD3, POMGNT1, POMT1, POMT2, SECISBP2, SGCA, SGCB, SGCD, SGCG, 
SPP1, SYNE2, TCAP, TRIM32
Congenital myopathy or muscular dystrophy (2)
RYR1, SEPN1
Metabolic myopathy (202)
AARS2, ACACA, ACAD9, ACADM, ACADVL, ACSF3, ACY1, ADCK3, AGK, AGL, AIFM1, ALDH1B1, ALDOA, ALG1, 
ALG11, ALG12, ALG13, ALG2, ALG3, ALG6, ALG8, ALG9, ALPL, AMACR, AMPD1, ATP5A1, ATP5E, ATP5G3, 
ATPAF2, B4GALT1, BCS1L, BRP44L, C10orf2, C12orf65, CACNA1S, COA5, COG1, COG4, COG5, COG6, COG7, 
COG8, COQ2, COQ4, COQ6, COQ9, COX10, COX14, COX15, COX20, COX4I2, COX6B1, COX7B, CPT1A, CPT1B, 
CPT2, CYC1, CYCS, D2HGDH, DARS2, DGUOK, DMGDH, DNA2, DOLK, DPM1, EARS2, ENO3, ETFA, ETFB, ETFDH, 
FARS2, FASTKD2, FOXRED1, GAA, GALC, GBE1, GFER, GFM1, GPR172B, GYG1, GYS1, HADH, HADHA, HADHB, 
HARS2, IARS, ISCU, LAMP2, LARS2, LDHA, LDHB, LIAS, LPIN1, LRPPRC, LYRM4, LYRM7, MARS, MATR3, MGAT2, 
MGME1, MPV17, MRPL12, MRPL3, MRPL44, MRPS16, MRPS22, MTFMT, MTHFD1, MTHFR, MTO1, NDUFA1, 
NDUFA10, NDUFA11, NDUFA12, NDUFA2, NDUFA4, NDUFA9, NDUFAF1, NDUFAF2, NDUFAF3, NDUFAF4, 
NDUFAF5, NDUFAF6, NDUFB3, NDUFB9, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS6, NDUFS7,
NDUFS8, NDUFV1, NDUFV2, NEU1, NFU1, NUBPL, OAT, OPA1, OXCT1, PDSS1, PDSS2, PEX12, PEX14, PEX26, 
PEX3, PEX5, PEX6, PEX7, PFKM, PGAM2, PGK1, PGM1, PHKA1, PHKA2, PHKB, PHKG2, PHYH, PMM2, PNPLA2, 
PNPT1, POLG, POLG2, PSAP, PTEN, PTRF, PUS1, PYGL, PYGM, RMND1, RRM2B, RSPH9, SCO1, SCO2, SDHA, 
SDHAF1, SDHAF2, SDHB, SDHC, SDHD, SLC22A5, SLC25A20, SLC25A3, SLC25A4, SUCLA2, SUCLG1, SURF1, 
TACO1, TARS2, TAZ, TIMM44, TK2, TMEM165, TMEM70, TSFM, TTC19, TYMP, UQCRB, UQCRC2, UQCRQ, VARS2, 
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YARS2
Motor neuron or Peripheral nerve disease (75)
AARS, AFG3L2, APTX, ARHGEF10, ATL1, ATXN2, BSCL2, CCT5, COLQ, DCTN1, DHTKD1, DNAJB2, DNMT1, 
DYNC1H1, EGR2, ELAVL4, ERLIN2, FAM134B, FGD4, FOXE1, GAN, GARS, GDAP1, GJB1, HARS, HINT1, HOXB1, 
HSPB1, HSPB3, HSPB8, HSPG2, IGHMBP2, IKBKAP, INF2, KARS, KIF1B, KIF5A, LITAF, MED25, MFN2, MPZ, 
MTMR2, MYH14, NAGA, NDRG1, NEFL, NGF, NIPA1, PDK3 , PLEKHG5, PLP1, PMP22, PNPLA6, PRX, RAB7A, 
REEP1, SACS, SBF2, SH3TC2, SLC12A6, SLC5A7, SMN1, SMN2, SNX25, SPTLC1, SPTLC2, SYNE1, TDP1, TFG, TGM6, 
TRPV4, UBA1, VRK1, WNK1, YARS
Myasthenic syndrome (12)
AGRN, CHAT, CHRNA1, CHRNB1, CHRND, CHRNE, DOK7, DPAGT1, GFPT1, LAMB2, MUSK, SCN4A
Cardiomyopathy (3)
MYBPC3, MYLK2, RYR2
Other candidate gene (207)
ACAD10, ACAD11, AIFM2, ATP5B, ATP5C1, ATP5D, ATP5F1, ATP5G1, ATP5G2, ATP5H, ATP5I, ATP5J, ATP5J2, 
ATP5L, ATP5O, ATP5S, ATPAF1, ATPIF1, C14orf2, CARS, CARS2, CD36, CHCHD1, CHCHD7, CMC1, CMC2, COA1, 
COA3, COA6, COQ10A, COQ10B, COQ3, COQ5, COQ7, COX11, COX16, COX17, COX18, COX19, COX4I1, COX5A, 
COX5B, COX6A1, COX6A2, COX6B2, COX6C, COX7A1, COX7A2, COX7A2L, COX7B2, COX7C, COX8A, COX8C, ECi1, 
ECSIT, EPRS, FARSA, FARSB, FRG1, FUNDC2, HINT3, IARS2, ICT1, LACTB, LYRM1, MCAT, MDH2, METTL17, 
MNF1, MRP63, MRPL1, MRPL10, MRPL11, MRPL13, MRPL14, MRPL15, MRPL16, MRPL17, MRPL18, MRPL19, 
MRPL2, MRPL20, MRPL21, MRPL22, MRPL23, MRPL24, MRPL27, MRPL28, MRPL30, MRPL32, MRPL33, MRPL34, 
MRPL35, MRPL36, MRPL37, MRPL38, MRPL39, MRPL4, MRPL40, MRPL41, MRPL42, MRPL43, MRPL45, MRPL46,
MRPL47, MRPL48, MRPL49, MRPL50, MRPL51, MRPL52, MRPL53, MRPL54, MRPL55, MRPL9, MRPS10, MRPS11, 
MRPS12, MRPS14, MRPS15, MRPS17, MRPS18A, MRPS18B, MRPS18C, MRPS2, MRPS21, MRPS23, MRPS24, MRPS25, 
MRPS26, MRPS27, MRPS28, MRPS30, MRPS31, MRPS33, MRPS34, MRPS35, MRPS36, MRPS5, MRPS6, MRPS7, 
MRPS9, MRS2, MTCH1, MTERF, MTG1, MTHFD1L, MTHFS, MTIF3, MTRF1L, NARS, NARS2, NDUFA3, NDUFA4L2, 
NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFAB1, NDUFB1, NDUFB10, NDUFB11, NDUFB2, NDUFB4, NDUFB5, 
NDUFB6, NDUFB7, NDUFB8, NDUFC1, NDUFC2, NDUFS5, NDUFV3, NIPSNAP3A, NRF1, OXA1L, OXSM, PARS2, 
PGAM1, POLRMT, PRELID1, PRELID2, PTCD1, PTCD2, PTCD3, PTRH2, QARS, RARS, SLIRP, SMCR7, SMCR7L, 
36
SUCLG2, TARS, TARSL2, TIMM21, TIMM23, TOMM70A, TOP1MT, TYMS, UQCR10, UQCR11, UQCRC1, UQCRFS1, 
UQCRH, USMG5, VARS, WARS, WARS2, YME1L1
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Appendix 2. List of Genes for targeted gene panel sequencing in Seoul National University Children’s 
Hospital (total 434 genes)
Muscular dystrophies (40)
DMD, EMD, FHL1, LMNA, SYNE1, SYNE2, TMEM43, TOR1A1P1, DUX4, SMCHD1, PTFR, MYOT, CAV3, DNAJB6, 
DES, TNPO3, HNRPDL, CAPN3, DYSF, SGCG, SGCA, SGCB, SGCD, TCAP, TRIM32, FKRP, TTN, POMT1, ANO5, 
FKTN, POMT2, POMGNTI, PLEC, TRAPPCI1, GMPPB, DAGI, DPM3, ISPD, VCP, LIMS2, GAA
Congenital muscular dystrophies (28)
LAMA2, COL6A1, COL6A2, COL6A3, SEPN1, FHL1, ITGA7, DNM2, TCAP, LMNA, FKTN, POMT1, POMT2, FKRP, 
POMGNTI, ISPD, POMGNT2, B3GNT1, GMPPB, LARGE, DPM1, DPM2, ALGI3, B3GALNT2, TMEM5, POMK, CHKB, 
ACTA1, TRAPC11
Distal myopathies (14)
DYSF, TTN, GNE, MYH7, MATR3, T1A1, MYOT, NEB, CAV3, LDB3, ANO5, KLHL9, DNM2, FLNC, VCP
Other myopathies (21)
ISCU, MSTN, FHL1, BAG3, ACVR1, MYOT, FLNC, LDB3, LAMP2, VCP, CAV3, SEPN1, DES, VMA21, PLEC, PABPN1, 
TTN, RYR1, CLN3, TRIM54, TRIM63, 
Myotonic syndromes (5)
DMPK, ZNF9, CAV3, HSPG2, ATP2A1
Ion channel muscle disease (7)




GAA, AGL, GBE1, PYGM, PFKM, PHKA1, PGM1, GYG1, GYS1, PRFAG2, RBCK1, PGK1, PGAM2, LDHA, ENP3, CPT2, 
SLC22A5, SLC25A20, ETFA, ETFB, ETFH, ACADVL, ABHD5, PNPLA2, ETFDH, LPIN1, 
Hereditary cardiomyopathies (69)
MYH6, MYH7, TNNT2, TPM1, MYBPC3, PRKAG2, TTNI3, MYL3, TTN, MYL2, ACCTC1, CSRP3, TNNC1, MYH6, VCL, 
MYLK2, MYOZ2, JPH2, PLN, NEXN, ANKRD1, ACTN2, NDUFAF1, TSFM, AARS2, MRP13, COX15, MTO1, MRPL44, 
LMNA, ACTN2, LDB3, TNNT2, SCN5A, DES, EYA4, SGCD, CSRP3, TCAP, ABCC9, PLN, ACTC1, TMPO, PSEN2, VCL, 
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TPM1, TNNC1, CRYAB, MYBC3, FCMD, TAZ, LAMA4, ILK, MYPN, RBM0, ANKRD1, TNN!3, MYH6, NEXN, SYNE1, 
MURC, DOLK, GATAD1, SDHA, TTN13, GAA, DTN4, FLNA
Congenital myasthenic syndromes (19)
CHRNA1, CHRNB1, CHRND, CHRNE, RAPSN, CHAT, COLQ, MUSK, DOK7, AGRN, DPAGT1, LAMB2, SCN4A, 
CHRNG, PLEC, ALG2, ALG14, SYT2, PREPL
Motor neuron disease (51)
SMN1, IGHMBP2, PLEKHG5, HSPB8, HSPB1, HSPB3, AARS, GARS, REEP1, SLC5A7, DCTN1, UBA1, ATP7A, DNAJB2, 
TRPV4, DYNC1H1, BICD2, FBXO38, ASAH1, VAPN, EXOSC8, SOD1, ALS2, SETX, FUS. ANG, TARDBP, FIG4, OPTN, 
ATXN2, VCP, UBQLN2, SIGMAR1, CHMP2B, PFN1, MATR3, NEFH. PRPH, C9orf72, CHCD10, SQSTM1, AT, GLE1, 
ERBB3, PIP5K1C, EXOSC3, SLC52AA3, SLC52A2, HEXB
Hereditary ataxia (45)
ATXN1, ATXN2, ATXN3, SPTBN2, CACNA1A, ATXN7, ATXN8OS, ATXN10, TTBK2, PPP2R2B, KCNC3, PRKCG, ITPR1, 
TBP, IFRD1, KCND3, PDYN, EEF2, FGF14, AFG3L2, BEAN1, TK2, ELOVL4, TGM6, NOP56, ELOVL5, CCDC88C, 
KCNA1, CACNB4, SLC1A3, FXN, TTPA, C10orf2,  APTX, SETX, SYNE1, ADCK3, TDP1, SIL1, POLG. ATM, MRE11A, 
SACS, PHYH, PEX7, RNF216
Hereditary motor and sensory neurpathies (63)
PMP22, MPZ, LITAF, EGR2, NEFL, HOXD10, ARHGEF10, FBLN5, DNM2, YARS, INF2, GNB4, DGDAP1, MTMR2, 
SBF2, SBF1, SH3TC2, NDRG1, PRX, HK1, FGD4, FIG4, SURF1, GJB1, AIFM1, PRPS1, PDK3, KIF1B, MFN2, RAB7A, 
TRPV4, GARS, HSPB1, HSPB8, AARS, DYNC1H1, LRSAM1, DHTKD1, TRIM2, TFG, MRAS, KIF5A, LMNA, MED25, 
DNAJB2, HINT1, KARS, PLEKHG5, COX6A1, IGHMBP2, SPTLC1, SPTLC2, ATL1, KIF1A, WNK1, IKBKAP, NGF, 
DNMT1, SLC12A6, GJB3, GAN, CTDP1, VRK1, SEPT9
Hereditary paraplegias (45)
ATL1, SPAST, NIPA1, KIAA0196, KIF5A, RTN2, HSPD1, BSCL2, REEP1, ZFYVE27, SLC33A1, CYP7B1, SPG7, SPG11, 
SFYVE26, ERLIN2, SPG20, SPG21, B4GALNT1, DDHD1, KIF1A, PNPLA6, C19orf12, GJC2, NT5C2, GBA2, AP4B1, 
AP5Z1, TECPR2, AP4M1, AP4E1, AP4S1, DDHD2, C12orf65, CYP2U1, ARL6IP1, AMPD2, ENTPD1, ALD3A2, L1CAM, 
PLP1, MYPAP, AFG3L2, SACS
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Other neuromuscular disorders (26)
TOR1A, SGCE, IKBKAP, TTR, KIF21A, PHOX2A, TUBB3, TPM2, MYH3, TNNI2, TNNT3, SYNE1, MYH8, POLG,
SLC25A4, C10orf2, POLG2, TK2, SUCLA2, OPA1, STIM1, ORAI1, PUS1, CHCHD10, CASQ1, YARS2
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초    록
서론: Collagen VI 연관형 근병증은 선천성 근이영양증 가운데 흔한
원인을 차지하고 있으며, 임상상이 다양하며 뚜렷한 치료방법이 없
어 치료 반응을 확인할 수 없으므로 그 진단이 매우 어려운 경우가
많다. 본 연구에서는, 유전자 검사로 확진된 collagen VI 연관형 근
병증 환자들의 임상적 특징 및 유전형의 다양성에 대해 기술 및 분
석하고자 하였다.
방법: 2000년 8월 1일부터 2016년 7월 31일까지 서울대학교 어린
이병원에 방문한 환자 중 선천성 근이영양증으로 진단받았으나 세
부 아형이 확진되지 않은 환자를 대상으로 유전자 패널 염기분석을
시행하였으며, 이 중 collagen VI 연관형 근병증의 원인유전자로 알
려진 COL6A1, COL6A2, COL6A3의 돌연변이가 확진된 23명의 환
자를 연구에 포함하였다. 의무기록 및 유전형에 대한 정보를 후향적
으로 수집하여 분석하였다.
결과: 23명 중 19명의 환자는 출생시부터의 근긴장 저하 (6명, 26%) 
혹은 24개월 이전에 인지된 운동발달지연 (13명, 56%)를 주소로 병
원에 내원하였다. 10명(34%)은 출생 시 하나 이상의 선천적 골격계
질환(선천 사경, 선천성 고관절 탈구, 관절 구축)에 대한 병력이 있
었다. 세 명(13%)의 환자는 혼자 걷는 능력을 획득하지 못하였으며, 
혼자 걸을 수 있었던 환자 중 7명(35%)은 평균 10세 경 걷는 능력
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을 상실하였다. 원위부 관절의 과신전, 근위부 관절의 구축, 척추측
만증이 각각 11명(48%)의 환자에서 확인되었으며, 척추측만증이 있
던 환자 중 3명은 수술적 치료를 시행받았다. 여섯 명(26%)의 환자
는 수면 시 기계보조환기를 사용하였다. 환자 개개인에 따라 다양한
임상상 및 경과를 보였다. 근육조직검사상 모든 환자는 근섬유막 특
이 collagen 결핍을 보였다. 임상적으로, 11명의 환자 (48%)가
Ullirch 타입 근이영양증으로 분류되었고 4명 (17%)은 Bethlem 타
입 근병증, 3명 (13%)은 지대근이영양증, 나머지 5명 (22%)는 어디
에도 속하지 않는 것으로 분류되었다. 15명(65%)의 환자가
COL6A1에 대한 돌연변이를 가지고 있었으며, COL6A2, COL6A3에
대한 돌연변이는 각각 3명(13%), 5명(22%)에서 보였다. 모든 환자
의 돌연변이는 이형 돌연변이였으며 대부분의 돌연변이는 3중 나선
구조 도메인에 위치했다. 이번 연구에서 총 5개의 돌연변이는 이전
에 보고된 적이 없는 것이었다. 돌연변이의 유전형과 임상형 간 의
미 있는 관련성은 발견되지 않았으며 출생 시 선척적 다중 관절 구
축이 있었던 경우 이른 시기부터 심한 증상을 보이는 경우가 많았
다.
결론: 이번 연구를 통해 collagen VI 연관형 근병증의 임상적, 조직
학적, 그리고 유전학적 다양성을 확인하였다. 유전형과 임상상의 연
관성은 뚜렷하지 않았으나 출생 시 다양한 근골격계 문제, 특히 다
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수의 관절 구축이 있는 경우 이후의 좋지 않은 예후를 보이는 경우
가 있어 비교적 이른 시기에 예후 예측 인자로 활용할 수 있을 것
으로 기대된다.
-----------------------------------------
주요어: collagen VI-연관형 근병증, Ullich 근이영양증, Bethlem 근
병증, COL6A1, COL6A2, COL6A3
